Sugi Predict

Sugi Predict / Compounds / SCHEMBL9161

SCHEMBL9161

SCHEMBL9161

CC(Sc1ncnc2[nH]cnc12)c1oc2ccc(Br)cc2c(=O)c1-c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSNK2B P67870 4/20 0.40
▸ PIK3CD O00329 3/20 0.40
▸ PIK3CG P48736 3/20 0.40
▸ PIM1 P11309 3/20 0.40
▸ CSNK2A2 P19784 3/20 0.40
▸ CDC7 O00311 2/20 0.40
▸ CSNK2A1 P68400 2/20 0.40
▸ PIK3R2 O00459 2/20 0.40
▸ PIM3 Q86V86 2/20 0.40
▸ PIM2 Q9P1W9 2/20 0.40
▸ CSNK2A3 Q8NEV1 1/20 0.40
▸ GABRP O00591 2/20 0.35
▸ GABRD O14764 2/20 0.35
▸ GABRA1 P14867 2/20 0.35
▸ GABRB1 P18505 2/20 0.35
▸ GABRG2 P18507 2/20 0.35
▸ GABRB3 P28472 2/20 0.35
▸ GABRA5 P31644 2/20 0.35
▸ GABRA3 P34903 2/20 0.35
▸ GABRA2 P47869 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30013651 1.00 CSNK2B (0.40) CSNK2BPIK3CDPIK3CGPIM1CSNK2A2
SCHEMBL17970725 0.90 PIK3CD (0.41) CSNK2BPIK3CDPIK3CGCSNK2A2CSNK2A1
SCHEMBL20748547 0.84 CDK1 (0.36) PIK3CDPIK3CGPIK3R2EGFR
SCHEMBL30670862 0.83 PIK3CD (0.44) CSNK2BPIK3CDPIK3CGPIM1CSNK2A2
SCHEMBL8270 0.83 PIK3CD (0.44) CSNK2BPIK3CDPIK3CGPIM1CSNK2A2
SCHEMBL8269 0.83 PIK3CD (0.44) CSNK2BPIK3CDPIK3CGPIM1CSNK2A2
SCHEMBL16589437 0.83 PIK3CD (0.44) CSNK2BPIK3CDPIK3CGPIM1CSNK2A2
SCHEMBL29651571 0.80 CDC7 (0.41) CSNK2BPIK3CDPIK3CGPIM1CSNK2A2
SCHEMBL9452 0.80 CDC7 (0.41) CSNK2BPIK3CDPIK3CGPIM1CSNK2A2
SCHEMBL8738 0.79 CDC7 (0.40) CSNK2BPIK3CDPIK3CGPIM1CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4292596-A1 METHOD AND COMBINATION FOR TREATING TUMORS Curon Biopharmaceutical (Shanghai) Co., Limited (CN) 2023-12-20 — — EP claimed
CN-117222413-A Methods and combinations for treating tumors 同润生物医药(上海)有限公司 2023-12-12 — — CN claimed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 — — US claimed
EP-2496567-B1 NOVEL BENZOPYRAN KINASE MODULATORS RHIZEN PHARMACEUTICALS S A (CH) 2017-07-12 — — EP claimed
US-20160318890-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2016-11-03 — — US claimed
US-9421209-B2 Kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2016-08-23 — — US claimed
US-20150174131-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2015-06-25 — — US claimed
US-9018375-B2 Substituted chromenes as kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2015-04-28 — — US claimed
US-20140080827-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2014-03-20 — — US claimed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 — — US claimed
EP-2496567-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2012-09-12 — — EP claimed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 — — US claimed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US claimed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 — — WO claimed
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 — — US disclosed
US-20240139198-A1 METHOD AND COMBINATION FOR TREATING TUMORS CURON BIOPHARMACEUTICAL (SHANGHAI) CO., LIMITED (CN) 2024-05-02 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150174131-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB CSNK2B 80/4885PIK3CD 70/4885PIK3CG 99/4885
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB CSNK2B 80/4885PIK3CD 70/4885PIK3CG 99/4885
US-20140080827-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB CSNK2B 80/4885PIK3CD 70/4885PIK3CG 99/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB CSNK2B 80/4885PIK3CD 70/4885PIK3CG 99/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB CSNK2B 80/4885PIK3CD 70/4885PIK3CG 99/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A CSNK2B 75/4885PIK3CD 103/4885PIK3CG 126/4885
US-20160318890-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB CSNK2B 80/4885PIK3CD 70/4885PIK3CG 99/4885
US-20240139198-A1 METHOD AND COMBINATION FOR TREATING TUMORS PDCD1, PDCD1LG2, CD274 CSNK2B 689/4885PIK3CD 116/4885PIK3CG 221/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB CSNK2B 80/4885PIK3CD 70/4885PIK3CG 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.